Henry Schein (NASDAQ:HSIC) Raised to Buy at Wall Street Zen

Wall Street Zen upgraded shares of Henry Schein (NASDAQ:HSIC) from a hold rating to a buy rating in a research report sent to investors on Friday.

Several other analysts have also commented on HSIC. Stifel Nicolaus reiterated a “hold” rating and set a $75.00 price objective (down previously from $80.00) on shares of Henry Schein in a report on Friday, July 25th. JPMorgan Chase & Co. decreased their price objective on Henry Schein from $80.00 to $76.00 and set an “overweight” rating for the company in a report on Thursday, August 7th. Barrington Research reissued an “outperform” rating and issued a $78.00 target price on shares of Henry Schein in a research report on Tuesday, September 23rd. UBS Group cut their price target on Henry Schein from $75.00 to $70.00 and set a “neutral” rating on the stock in a research report on Wednesday, August 6th. Finally, Evercore ISI raised Henry Schein from an “in-line” rating to an “outperform” rating and set a $83.00 price target on the stock in a research report on Tuesday, August 26th. Five investment analysts have rated the stock with a Buy rating and eight have issued a Hold rating to the company’s stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus target price of $76.67.

Henry Schein Stock Up 1.5%

Henry Schein stock opened at $67.03 on Friday. The business has a fifty day moving average of $67.93 and a two-hundred day moving average of $69.00. The company has a quick ratio of 0.78, a current ratio of 1.41 and a debt-to-equity ratio of 0.51. The firm has a market cap of $8.13 billion, a P/E ratio of 21.62, a P/E/G ratio of 2.18 and a beta of 0.81. Henry Schein has a twelve month low of $60.56 and a twelve month high of $82.49.

Henry Schein (NASDAQ:HSIC) last issued its quarterly earnings data on Tuesday, August 5th. The company reported $1.10 EPS for the quarter, missing the consensus estimate of $1.19 by ($0.09). Henry Schein had a net margin of 3.05% and a return on equity of 14.36%. The business had revenue of $3.24 billion for the quarter, compared to analysts’ expectations of $3.22 billion. During the same quarter in the prior year, the company posted $1.23 EPS. The business’s revenue for the quarter was up 3.3% on a year-over-year basis. Henry Schein has set its FY 2025 guidance at 4.800-4.940 EPS. On average, analysts forecast that Henry Schein will post 4.74 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of HSIC. CYBER HORNET ETFs LLC purchased a new position in Henry Schein in the 2nd quarter worth approximately $25,000. MUFG Securities EMEA plc acquired a new stake in Henry Schein in the 2nd quarter valued at approximately $27,000. Rakuten Securities Inc. acquired a new stake in Henry Schein in the 1st quarter valued at approximately $34,000. ANTIPODES PARTNERS Ltd acquired a new stake in Henry Schein in the 2nd quarter valued at approximately $43,000. Finally, Steph & Co. acquired a new position in shares of Henry Schein in the second quarter worth $44,000. 96.62% of the stock is owned by hedge funds and other institutional investors.

About Henry Schein

Henry Schein, Inc provides health care products and services to dental practitioners, laboratories, physician practices, and ambulatory surgery centers, government, institutional health care clinics, and other alternate care clinics worldwide. It operates through two segments, Health Care Distribution, and Technology and Value-Added Services.